Differential properties of dentate gyrus and CA1 neural precursors.
In the present article we investigated the properties of CA1 and dentate gyrus cell precursors in adult rodents both in vivo and in vitro. Cell proliferation in situ was investigated by rating the number of cells incorporating BrdU after kainate-induced seizures. CA1 precursors displayed a greater proliferation capacity than dentate gyrus precursors. The majority of BrdU-labeled cells in CA1 expressed Nestin and Mash-1, two markers of neural precursors. BrdU-positive cells in the dentate gyrus expressed Nestin, but only a few expressed Mash-1. In animals pretreated with the antimitotic azacytidine, the capacity of kainate to enhance the proliferation was higher in CA1 than in the dentate gyrus. Differences in intrinsic progenitor cell activity could underlie these different expansion capacities. Thus, we compared the renewal- expansion and multipotency of dentate gyrus and CA1 precursors isolated in vitro. We found that the dissected CA1 region, including the periventricular zone, is enriched in neurosphere-forming cells (presumed stem cells), which respond to either EGF or FGF-2. Dentate gyrus contains fewer neurosphere-forming cells and none that respond to FGF-2 alone. Neurospheres generated from CA1 were multipotent and produced neurons, astrocytes, and oligodendrocytes, while dentate gyrus neurospheres mostly produced glial cells. The analysis of the effects of EGF on organotypic cultures of hippocampal slices depicted similar features: BrdU and Nestin immunoreactivities increased after EGF treatment in CA1 but not in the dentate gyrus. These results suggest that CA1 precursors are more stem-cell-like than granule cell precursors, which may represent a more restricted precursor cell.
INMED/INSERM U29, Marseille, France.
H
H
Becq
I
I
Jorquera
Y
Y
Ben-Ari
S
S
Weiss
A
A
Represa
D000704:Analysis of Variance; D000818:Animals; D001374:Azacitidine / Q000494:pharmacology; D051792:Basic Helix-Loop-Helix Proteins; D001973:Bromodeoxyuridine / Q000378:metabolism; D002452:Cell Count / Q000379:methods; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000378:metabolism; D018891:Dentate Gyrus / Q000166:cytology* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004791:Enzyme Inhibitors; D004815:Epidermal Growth Factor / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists / Q000633:toxicity; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006624:Hippocampus / Q000166:cytology*; D007150:Immunohistochemistry / Q000379:methods; D066298:In Vitro Techniques; D007381:Intermediate Filament Proteins / Q000378:metabolism; D007608:Kainic Acid / Q000633:toxicity; D051379:Mice; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064231:Nestin; D009474:Neurons / Q000166:cytology* / Q000187:drug effects; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D018709:Statistics, Nonparametric; D013234:Stem Cells / Q000166:cytology* / Q000187:drug effects; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism
D001374:Azacitidine; D051792:Basic Helix-Loop-Helix Proteins; D001973:Bromodeoxyuridine; D004268:DNA-Binding Proteins; D004791:Enzyme Inhibitors; D004815:Epidermal Growth Factor; D018690:Excitatory Amino Acid Agonists; D016222:Fibroblast Growth Factor 2; D007381:Intermediate Filament Proteins; D007608:Kainic Acid; D009419:Nerve Tissue Proteins; D064231:Nestin; D010751:Phosphopyruvate Hydratase; D014157:Transcription Factors; C499317:Ascl1 protein, mouse; C577485:Nes protein, mouse